Technical Analysis for AVXL - Anavex Life Sciences Corp.

Grade Last Price % Change Price Change
grade F 2.45 -0.81% -0.02
AVXL closed down 0.81 percent on Monday, November 11, 2019, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AVXL trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -0.81%
Lower Bollinger Band Walk Weakness -0.81%
BB Squeeze + Lower Band Touch Range Contraction -0.81%
Below Lower BB Weakness -0.81%

Older signals for AVXL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.
Biopharmaceutical Pain Chemical Compounds Cancers Neuroscience Alzheimer's Disease Alzheimer's Treatment Of Alzheimer's Disease Central Nervous System Diseases Piperidines Nootropics
Is AVXL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.09
52 Week Low 1.25
Average Volume 346,918
200-Day Moving Average 2.8823
50-Day Moving Average 2.925
20-Day Moving Average 2.727
10-Day Moving Average 2.669
Average True Range 0.1622
ADX 17.43
+DI 14.9398
-DI 26.3849
Chandelier Exit (Long, 3 ATRs ) 2.4734
Chandelier Exit (Short, 3 ATRs ) 2.8866
Upper Bollinger Band 2.9652
Lower Bollinger Band 2.4888
Percent B (%b) -0.08
BandWidth 17.469747
MACD Line -0.1073
MACD Signal Line -0.0795
MACD Histogram -0.0279
Fundamentals Value
Market Cap 103.32 Million
Num Shares 42.2 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -6.45
Price-to-Sales 0.00
Price-to-Book 7.34
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.60
Resistance 3 (R3) 2.60 2.55 2.58
Resistance 2 (R2) 2.55 2.51 2.55 2.57
Resistance 1 (R1) 2.50 2.49 2.48 2.50 2.56
Pivot Point 2.45 2.45 2.44 2.45 2.45
Support 1 (S1) 2.40 2.41 2.38 2.40 2.34
Support 2 (S2) 2.35 2.39 2.35 2.33
Support 3 (S3) 2.30 2.35 2.33
Support 4 (S4) 2.30